News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Today on Medscape
Business of Medicine
Medical Lifestyle
Science & Technology
Medical Students
Nurses
Pharmacists
Residents
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Monday, August 15, 2022
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Perspective > Medscape Pharmacists > Food and Drug Administration Approvals

      May 2004

      Jane S. Ricciuti, RPh, MS

      Disclosures

      June 03, 2004

      In This Article

      Respiratory Agents

      Advair Diskus
      (fluticasone propionate/salmeterol xinafoate) Inhalation

      Manufacturer: GlaxoSmithKline

      Drug Approval Classification: Supplemental New Drug Application (Approval Date: 4/21/04)

      Indication: This supplemental NDA provides for the use of Advair Diskus (fluticasone propionate/salmeterol xinafoate) Inhalation 100/50 mcg in children 4-11 years of age with asthma.

      Advair Diskus (Fluticasone propionate/salmeterol xinafoate) Inhalation Letter

      Advair Diskus (Fluticasone propionate/salmeterol xinafoate) Inhalation

      processing....

      Feedback
      Help us make reference on Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this article more useful to clinicians.
      Pleasedo not use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate
      Editions
      English Deutsch Español Français Português
      All material on this website is protected by copyright, Copyright © 1994-2022 by WebMD LLC. This website also contains material copyrighted by 3rd parties.